...
首页> 外文期刊>Oncogene >Adenoviral E1B55K oncoprotein sequesters candidate leukemia suppressor sequence-specific single-stranded DNA-binding protein 2 into aggresomes
【24h】

Adenoviral E1B55K oncoprotein sequesters candidate leukemia suppressor sequence-specific single-stranded DNA-binding protein 2 into aggresomes

机译:腺病毒E1B55K癌蛋白螯合候选白血病抑制基因序列特异性单链DNA结合蛋白2进入聚集体

获取原文

摘要

Sequence-specific single-stranded DNA-binding protein 2 (SSBP2) is a candidate tumor suppressor for human acute myelogenous leukemia (AML). Inducible expression of SSBP2 causes growth arrest and partial differentiation in AML cells. Here, we report that the adenoviral oncoprotein E1B55K directly binds to endogenous SSBP2 protein and sequesters it into juxtanuclear bodies in adenovirally transformed human embryonic kidney (HEK) 293 cells. Similarly, transient expression of E1B55K in IMR90 fibroblasts and HeLa cells result in the formation of juxtanuclear bodies containing SSBP2. When nuclear export of E1B55K is prevented, SSBP2 remains associated with E1B55K in nuclear foci. A requirement for intact microtubules to retain the integrity of the juxtanuclear bodies suggests them to be E1B55K containing aggresomes. The adenoviral E1B55K protein has been shown to localize to the Mre11 complex and p53 to aggresome structures; together with the viral E4orf6 protein, E1B55K recruits a cellular E3 ubiquitin ligase that induces degradation of Mre11 and p53. However, our present studies reveal that E1B55K does not degrade SSBP2. These data demonstrate that E1B55K targets the candidate leukemia suppressor SSBP2 and suggest that subverting its function may contribute to cell transformation by viral oncoproteins.
机译:序列特异性单链DNA结合蛋白2(SSBP2)是人类急性骨髓性白血病(AML)的候选肿瘤抑制剂。 SSBP2的诱导表达导致AML细胞的生长停滞和部分分化。在这里,我们报告腺病毒癌蛋白E1B55K直接与内源性SSBP2蛋白结合,并将其隔离到腺病毒转化的人类胚胎肾(HEK)293细胞的近核体内。同样,IMR90成纤维细胞和HeLa细胞中E1B55K的瞬时表达导致含有SSBP2的近核体的形成。当阻止E1B55K的核输出时,SSBP2在核病灶中仍与E1B55K相关。需要完整的微管来保持近核体的完整性,这表明它们是包含E1B55K的聚集体。已显示腺病毒E1B55K蛋白位于Mre11复合体,p53位于聚集体结构。 E1B55K与病毒E4orf6蛋白一起募集了一种细胞E3泛素连接酶,该酶诱导Mre11和p53降解。但是,我们目前的研究表明E1B55K不会降解SSBP2。这些数据表明E1B55K靶向候选的白血病抑制物SSBP2,并表明颠覆其功能可能有助于病毒癌蛋白转化细胞。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号